Siemens Healthineers joins Bio-Hermes-002 Study for Alzheimer’s research

The Global Alzheimer’s Platform Foundation (GAP) has announced that Siemens Healthineers has joined the Bio-Hermes-002 study alongside several other industry leaders. Siemens is now a licensed partner of the study, aiming to enhance Alzheimer’s diagnostics.

Specifically, Siemens Healthineers will work to “change the paradigm of early-stage disease diagnostics and monitoring, building upon findings from Bio-Hermes-001.” The Bio-Hermes-002 study will analyze biomarker data stored on the secure AD Workbench to “assess, diagnose or predict” disease presence/risk.